Alpha Tau is a biotech company that enables highly potent and conformal alpha-irradiation of solid tumors.
Alpha Tau Medical focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy) for the treatment of solid cancer tumors.
Alpha Tau was founded in 2016 by Prof. Itzhak Kelson and Prof. Yona Keisari. The company is headquartered in Tel Aviv, Israel, with an office in Boston, Massachusetts.
Alpha Tau Medical, the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT. The company successfully completed its first-in-human clinical trial of Alpha DaRT with squamous cell carcinoma patients from Italy and Israel.
Alpha Tau is backed by Shavit Capital, Medison Ventures, OurCrowd and others. The company raised $26M in Series B round on June 04, 2020. This brings Alpha Tau's total funding to $55M to date.